The Opthea failed trial will probably keep the handbrake on here as we head into Renal Cohort A (P1/2) GvHD (P2) and Knee OA (P3) results over the next 3, 9 and 12(ish) months. Regardless, it's still pretty exciting that we will know so much more about what Cymerus iPSC MSCs can do by this time next year. At <US$100M (and especially <US$30M) market cap, there's a good risk : reward on offer IMO.
The Opthea failed trial will probably keep the handbrake on here...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.5¢ | $39.66K | 238.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 277684 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 14285 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |